Abstract:ObjectiveTo analyze the expression of microthromia-associated transcription factor (MITF) mRNA in laryngeal cancer and its adjacent tissues,and to speculate its clinical significance. Methods A total of 33 patients with laryngeal cancer who received treatment at Nanjing Drum Tower Hospital from March 2014 to June 2016 were selected,and their fresh specimens of laryngeal cancer and adjacent tissues were collected.Tissue RNA was extracted,expression of MITF mRNA was detected by qPCR,and clinicopathological data of patients were collected for statistical analysis. Results The ΔCt value of MITF mRNA in laryngeal carcinoma was significantly lower than that in the corresponding adjacent tissues (10.01±4.61 vs 7.64±6.57,P=0.016).There was no significant difference in the expression of MITF mRNA in different age (P=0.259),T stage (P=0.118),lymph node metastasis (P=1.000),tumor site (P=0.079),and differentiation degree (P=0.481).However,the expression of MITF mRNA in patients with stage Ⅲ and Ⅳ laryngeal cancer was significantly higher than that in patients with stageⅠ and Ⅱ laryngeal cancer (P=0.039).The median total survival time of 33 patients with low expression of MITF was 29 months (12-52 months),and that of the patients with high expression was 30 months (8-56 months),and there was no significant difference between the two groups(χ²=1.594,P=0.207). ConclusionThe expression of MITF gene in laryngeal cancer is higher than that in adjacent tissues,and the expression of MITF mRNA in advanced laryngeal cancer is higher than that in early laryngeal cancer.The expression of MITF gene may be related to the occurrence and development of laryngeal cancer.